Publications

  1. Johnson DR, Hunt CH, Nathan MA, Parisi JE, Boeve BF, Murray ME, Knopman DS, Jack CR Jr, Petersen RC, Lowe VJ, Johnson GB. Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. J Neurooncol. 2017 Nov 8 Epub 2017 Nov 08
    View PubMed
  2. Delivanis DA, Bancos I, Atwell TD, Schmit GD, Eiken PW, Natt N, Erickson D, Maraka S, Young WF, Nathan MA. Diagnostic performance of unenhanced computed tomography and 18 F-fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours. Clin Endocrinol (Oxf). 2017 Aug 17 [Epub ahead of print]
    View PubMed
  3. Jasim S, Nathan MA, Bible KC. "Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. Endocrine. 2017 Jul; 57 (1):187-188 Epub 2017 May 16
    View PubMed
  4. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71 (3):340-348 Epub 2016 Sept 03
    View PubMed
  5. Parker WP, Evans JD, Stish BJ, Park SS, Olivier K, Choo R, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ, Davis BJ. Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2017 Mar 01; 97: (3)526-535.
    View PubMed
  6. Arnett ALH, Merrell KW, Martin Macintosh E, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL. Utility of (18)F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. J Thorac Oncol. 2017 Jan; 12 (1):121-128 Epub 2016 Aug 26
    View PubMed
  7. Delivanis DA, Erickson D, Atwell TD, Natt N, Maraka S, Schmit GD, Eiken PW, Nathan MA, Young WF Jr, Bancos I. Procedural and clinical outcomes of percutaneous adrenal biopsy in a high-risk population for adrenal malignancy. Clin Endocrinol (Oxf). 2016 Nov; 85 (5):710-716 Epub 2016 June 20
    View PubMed
  8. McLaren RH, Mynderse LA, Davis BJ, Kwon ED, Lowe VJ, Nathan MA, Karnes R, Parker WP. The Utility of C11 Choline PET/CT in Post-prostatectomy Patients with Biochemical Recurrence: a Comparison to mpMRI. World Jnl of Urol.2016;().
  9. Evans JD, Davis BJ, Stish BJ, Park SS, Olivier K, Choo CR, Nathan MA, Welch BT, Karnes RJ, Mynderse LA, Pisansky TM, Kwon ED, Lowe VJ. Recurrence Patterns of Oligometastatic Disease Detected Using C-11 Choline Positron Emission Tomography/Computed Tomography in Patients With a Rising Prostate-Specific Antigen Level Following Postprostatectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96: (2S)S103.
    View PubMed
  10. Parker WP, Davis BJ, Park SS, Olivier K, Choo CR, Nathan MA, Lowe VJ, Welch TJ, Zaid HB, Sobol II, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes JR, Kwon ED. Patterns of Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: Unique Identification of Sites of Recurrence Impacting Clinical Management. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96: (2S)S112.
    View PubMed
  11. Broski SM, Johnson GB, Howe BM, Nathan MA, Wenger DE, Spinner RJ, Amrami KK. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol. 2016 Aug; 45 (8):1097-105 Epub 2016 Apr 26
    View PubMed
  12. Lehman VT, Murphy RC, Schenck LA, Carter RE, Johnson GB, Kotsenas AL, Morris JM, Nathan MA, Wald JT, Maus TP. Comparison of facet joint activity on 99mTc-MDP SPECTCT with facet joint signal change on MRI with fat suppression. Diagn Interv Radiol. 2016 May-Jun; 22: (3)277-83.
    View PubMed
  13. Broski SM, Moran EK, Glazebrook KN, Nathan MA. BRAF Inhibitor-Induced Panniculitis: Appearance on 18F-FDG PETCT. Clin Nucl Med. 2016 Mar; 41: (3)e149-51.
    View PubMed
  14. Delivanis DA, Erickson DZ, Atwell TD, Maraka S, Schmit GD, Eiken PW, Nathan MA, Young WF Jr.. Procedural and clinical outcomes of percutaneous adrenal biopsy in high-risk population for adrenal malignancy Clin Endocrinol.2016;().
  15. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, Kawashima A. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014 Feb; 55: (2)223-32.
    View PubMed
  16. Kitajima K, Murphy RC, Nathan MA, Sugimura K. Update on positron emission tomography for imaging of prostate cancer. Int J Urol. 2014 Jan; 21: (1)12-23.
    View PubMed
  17. Howe BM, Amrami KK, Nathan MA, Garcia JJ, Spinner RJ. Perineural spread of cervical cancer to the sciatic nerve. Skeletal Radiol. 2013 Nov; 42 (11):1627-31 Epub 2013 June 11
    View PubMed
  18. Babu MA, Spinner RJ, Dyck PJ, Amrami KK, Nathan MA, Kawashima A, Howe BM. Recurrent prostatic adenocarcinoma with perineural spread to the lumbosacral plexus and sciatic nerve: comparing high resolution MRI with torso and endorectal coils and F-18 FDG and C-11 choline PET/CT. Abdom Imaging. 2013 Oct; 38: (5)1155-60.
    View PubMed
  19. Kitajima K, Murphy RC, Nathan MA. Choline PETCT for imaging prostate cancer: an update. Ann Nucl Med. 2013 Aug; 27: (7)581-91.
    View PubMed
  20. Froemming AT, Kawashima A, Takahashi N, Hartman RP, Nathan MA, Carter RE, Yu L, Leng S, Kagoshima H, McCollough CH, Fletcher JG. Individualized kV selection and tube current reduction in excretory phase computed tomography urography: potential for radiation dose reduction and the contribution of iterative reconstruction to image quality. J Comput Assist Tomogr. 2013 Jul-Aug; 37(4):551-9.
    View PubMed
  21. Lingle WL, Negron V, Johnson GB, Nathan MA, Parasi JE, Johnson AJ, Hunt CH, Peller PJ, Broski SM, Fauq AH, Jack CR, Petersen RC, Klunk WE, Mathis CA, Lowe V. Adapting a pet imaging agent for correlative microscopy of meningiomas and other intracranial tumors Microscopy and Microanalysis. 2012; 18:178-9.
  22. Bogsrud TV, Hay ID, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Bjoro T, Lowe VJ. Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl Med Commun. 2011 Apr; 32: (4)245-51.
    View PubMed
  23. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Bjoro T, Hay ID, Lowe VJ. The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma. Mol Imaging Biol. 2010 Oct; 12(5):547-53. Epub 2009 Dec 01.
    View PubMed
  24. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, Johnston PB, Wiseman GA. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol. 2010 Jul; 75(1):e68-73. Epub 2009 Aug 27.
    View PubMed
  25. Murphy R, Doerger KM, Nathan MA, Lowe VJ. Pretreatment with diphenoxylate hydrochloride/atropine sulfate (Lomotil) does not decrease physiologic bowel FDG activity on PET/CT scans of the abdomen and pelvis. Mol Imaging Biol. 2009 Mar-Apr; 11 (2):114-7 Epub 2008 Nov 27
    View PubMed
  26. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Kasperbauer JL, Reading CC, Hay ID, Lowe VJ. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid. 2008 Jul; 18(7):713-9.
    View PubMed
  27. Karantanis D, O'eill BP, O'Neill BP, Subramaniam RM, Witte RJ, Mullan BP, Nathan MA, Lowe VJ, Peller PJ, Wiseman GA. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun. 2007 Nov; 28: (11)834-41.
    View PubMed
  28. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, Peller PJ, Bahn RS, Lowe VJ. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nucl Med. 2007 Jun; 48: (6)896-901.
    View PubMed
  29. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun. 2007 May; 28(5):373-81.
    View PubMed
  30. Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol. 2006 Nov; 187: (5)1361-7.
    View PubMed
  31. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, Rohren E, Wiersema MJ, Vazquez-Sequeiros E, Murray JA, Allen MS, Levy MJ, Clain JE. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005 Nov-Dec; 7 (6):422-30
    View PubMed
  32. Lindell RM, Hartman TE, Swensen SJ, Jett JR, Midthun DE, Nathan MA, Lowe VJ. Lung cancer screening experience: a retrospective review of PET in 22 non-small cell lung carcinomas detected on screening chest CT in a high-risk population. AJR Am J Roentgenol. 2005 Jul; 185: (1)126-31.
    View PubMed
  33. Foley TA, Earnest F IV, Nathan MA, Hough DM, Schiller HJ, Hoskin TL. Differentiation of non-perforated and perforated appendicitis: accuracy of CT diagnosis and relationship of CT findings to hospital length of stay. Radiology. 2005 Apr; 235(1):89-96.
    View PubMed
  34. Foley TA, Earnest F, Nathan MA, Hough DM, Schiller HJ, Hoskin TL. Differentiation of nonperforated from perforated appendicitis: accuracy of CT diagnosis and relationship of CT findings to length of hospital stay. Radiology. 2005 Apr; 235: (1)89-96.
    View PubMed
  35. Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, Chari ST. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: Retrospective review of CT scans obtained before diagnosis. Am J Roentgenol. 2004 Apr; 182(4):897-903.
    View PubMed
  36. Bushnell DL, Madsen M, Kahn D, Nathan M, Williams RD. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: Potential for increasing delivery of therapeutic agents. Nucl Med Commun. 1999; 20:875-81.
    View PubMed
  37. Nathan MA, Abu-Yousef MM. The "vascular pedicle sign" in the diagnosis of pelvic masses. JDMS. 1997; 13:28-31.
  38. Murphy SP, Nathan MA, Karwal MW. FDG-PET appearance of pelvic Castleman's disease: Correlation with CT. J Nucl Med. 1997; 38:1211-12.
    View PubMed
  39. Nathan MA, Seabold JE, Brown BP, Bushnell DL. Colonic localization of labeled leukocytes in critically ill patients: Scintigraphic detection of pseudomembranous colitis. Clin Nucl Med. 1995; 20:99-106.
    View PubMed
  40. Varney NR, Bushnell DL, Nathan MA, Kahn D, Roberts R, Rezai K, Walker W, Kirchner PT. NeuroSPECT correlates of disabling mild head injury: Preliminary findings. J Head Trauma Rehabilitation. 1995; 10:18-28.
  41. Cook EH, Metz JT, Leventhal B, Lebovitz M, Nathan M, Semerdjian SA, et al. Fluoxetine effects on cerebral glucose metabolism. Neuroreport. 1994; 5:1745-8.
    View PubMed
  42. Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen MT, Kirchner PT. Diagnosis of recurrent brain tumor: Value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. AJR. 1994; 163:1459-65.
    View PubMed
  43. Nathan MA, Bushnell DL, Kahn D, Simonson TM, Kirchner PT. Crossed cerebellar diaschisis associated with balloon occlusion of the carotid artery. Nucl Med Commun. 1994; 15:448-54.
    View PubMed
  44. Madsen MT, Kirchner PT, Edlin JP, Nathan MA, Kahn D. An emission-based technique for obtaining attenuation correction data for myocardial SPECT studies. Nucl Med Commun. 1993; 14:689-95.
    View PubMed